Genetically speaking, more than 90% of HHT patients show mutations in ENG or ACVRL1/ALK1 genes, both belonging to the TGF-β/BMP9 signaling pathway. Here, ACVRL1 is linked to hereditary hemorrhagic telangiectasia.